Importantly, patients whose tumour had BRAF or PIK3CA mutation had shorter PFS regardless of whether cetuximab was administered in the second, or third and higher lines (interaction tests P=0.5 and 0.6, respectively). The gene discussed is PIK3CA; the disease is neoplasm.